Long-Term Data Affirm First-Line Immunotherapy for Advanced Esophageal Cancer
(MedPage Today) -- SAN FRANCISCO -- A chemoimmunotherapy combination significantly improved long-term survival in advanced esophageal cancer as compared with chemotherapy, follow-up data from a randomized trial showed.
Pembrolizumab (Keytruda...
Source: MedPage Today Gastroenterology - Category: Gastroenterology Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Esophagus Cancer | Gastroenterology | Immunotherapy